Cardiac Toxicity Following High-Dose Cyclophosphamide, Cisplatin, and BCNU (STAMP-1) for Breast Cancer

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 2 A, 2000, Pages 198-203

  Nieto, Yago ^a   Cagnoni, Pablo J ^a   Bearman, Scott I ^a   Shpall, Elizabeth J ^a   Matthes, Steve ^a   Jones, Roy B ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Bone marrow transplantation; Breast cancer; Cardiac toxicity; Cyclophosphamide; Stem cell transplant

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; STAMP I PROTOCOL; STAMP-I PROTOCOL;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; AUTOTRANSPLANTATION; BREAST TUMOR; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; FEMALE; HEART ARRHYTHMIA; HEART STROKE VOLUME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MIDDLE AGED; RADIOTHERAPY; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; ARRHYTHMIA; BREAST NEOPLASMS; CARDIOMYOPATHIES; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TRANSPLANTATION, AUTOLOGOUS; X-RAY THERAPY;

EID: 0033656976     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70043-7     Document Type: Article

References (32)

1. Peters WP, Eder JP, Henner WD, et al. High-dose combination chemotherapy with autologous bone marrow support: a phase I trial. J Clin Oncol. 1986;4:646-654.
2. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination chemotherapy with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368-1376.
3. Jones RB, Shpall EJ, Ross M, Bast R, Affronti M, Peters WP. AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer: current results. Proc Am Soc Clin Oncol. 1990;7:121.
4. Nieto Y, Cagnoni PJ, Shpall EJ, et al. Prospective phase II study of high-dose chemotherapy with autologous stem cell transplant for patients with stage IV breast cancer with minimal metastases. Clin Cancer Res. 1999;5:1731-1737.
5. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132-1143.
6. Bearman SI, Overmoyer BA, Bolwell BJ, et al. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. Bone Marrow Transplant. 1997;20:931-937.
7. Cagnoni PJ, Nieto Y, Shpall EJ, et al. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol. 1998;16:1661-1668.
8. Peters WP, Jones RB, Vredenburgh J, et al. A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol. 1996;15:121a.
9. Peters WP, Rosner G, Vredenburgh J, et al. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Soc Clin Oncol. 1999;18:1a.
10. Ross M, Dukelow K, Gilbert C, et al. Outpatient bone marrow transplantation: two year update. Proc Am Soc Clin Oncol. 1995; 14:316a.
11. Jones RB, Matthes S, Shpall EJ, et al. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst. 1993;85:640-647.
12. Fisher DC, Sherrill GB, Hussein AM, et al. Thrombotic angiopathy (TMA) as a complication of high-dose chemotherapy for breast cancer. Proc Am Soc Clin Oncol. 1995;14:317a.
13. Brown MS, Stemmer SM, Simon JH, et al. White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. Am J Neuroradiol. 1998;19:217-221.
14. Nieto Y, Cagnoni PJ, Bearman SI, et al. Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. Clin Cancer Res. 1999;5:501-506.
15. Crews JR, Vredenburgh J, Bigner S, et al. Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) after high-dose chemotherapy (HDC) and autologous bone marrow transplant (ABMT). Proc Am Soc Clin Oncol. 1995;14:317a.
16. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest Nev Drugs. 1992;10:239-253.
17. Jones RB, Matthes S, Dufton C, et al. Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin and BCNU in patients with breast cancer. Breast Cancer Res Treat. 1993;26:S11-S17.
18. El-Yazigi A, Martin C. Improved analysis of cyclophosphamide by capillary gas chromatography with thermionic (nitrogenphosphorus) detection and silica sample purification. J Chromatogr. 1986;74:177-182.
19. Tew K, Colvin OM, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. 2nd ed. Philadelphia, PA: Lippincott-Raven, 1996.
20. Slavin RE, Millan JC, Mullins GM. Pathology of high dose intermittent cyclophosphamide therapy. Hum Pathol. 1975;693-709.
21. Appelbaum FR, Strauchen JA, Graw RG, et al. Acute lethal carditis caused by high-dose combination chemotherapy: a unique clinical and pathological entity. Lancet 1976;1:58-62.
22. Mills BA, Roberts RW. Cyclophosphamide-induced cardiomyopathy: a report of two cases and review of the English literature. Cancer. 1979;43:2223-2226.
23. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:758-763.
24. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68:1114-1118.
25. Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications after bone marrow transplantation: a report on a series of 63 consecutive transplantations. Cancer. 1986;57:2061-2069.
26. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol. 1992;10:995-1000.
27. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1977; 91:710-717.
28. Bearman SI, Petersen FB, Schor RA, et al. Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant. 1990;5:173-177.
29. Hertenstein B, Stefanic M, Schmeiser T, et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologie evaluation before transplant. J Clin Oncol. 1994;12:998-1004.
30. Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol. 1998;16:3796-3802.
31. Kakavas PW, Ghalie R, Parrillo JE, Kaizer H, Barron JT. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant. 1995;15:859-861.
32. Nieto Y, Xu X, Cagnoni PJ, et al. Nbnpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. Clin Cancer Res. 1999;5:747-751.